Slide 1: 2010 Earnings & 2011 Outlook Conference Call
1 TELEFLEX INCORPORATED 2010 EARNINGS & 2011 OUTLOOK CONFERENCE CALL Exhibit 99.1
Slide 2: Conference Call Logistics
2 Conference Call Logistics The release, accompanying slides, and replay webcast available online at www.teleflex.com (click on "Investors") Telephone replay available by dialing 888-286-8010 or for international calls, 617- 801-6888, pass code number 84161006
Slide 3: Introductions
3 Introductions Benson Smith Chairman, President and CEO Randy Meier Executive Vice President and CFO Jake Elguicze Vice President, Investor Relations
Slide 4: Forward-Looking Statements/Additional Notes
4 4 4 4 4 4 Forward-Looking Statements/Additional Notes This presentation and our discussion contain forward-looking information and statements including, but not limited to, our expectation that the VasoNova business will be accretive to revenue and earnings by year-end 2011; longer-term growth and
Slide 5: Highlights
HIGHLIGHTS Teleflex:
Slide 6: 2010 Highlights
6 2010 Highlights Significant portfolio transformation progress made to med-tech company Focus on devices that provide leadership position for access into the body Divested additional non-core / cyclical assets Full year research & development spending up 16% to 2.4% of revenue New product introduct
Slide 7: 2011 Recent Developments
7 2011 Recent Developments VasoNova acquisition Unique central venous catheter navigation technology that allows for real-time accurate confirmation of catheter placement Expands existing vascular access product offerings Expected to be accretive to revenue and earnings by year-end 2011 CEO leadersh
Slide 8: "High-Five" Goals
8 "High-Five" Goals Some progress made...more work to be done
Slide 9: Fourth Quarter & Full Year 2010 Financial Review
9 FOURTH QUARTER & FULL YEAR 2010 FINANCIAL REVIEW
Slide 10: Fourth Quarter Results
10 Fourth Quarter Results Revenue of $493 million, up 1%; up 3% constant currency Medical constant currency revenue growth of 1% Aerospace constant currency revenue growth of 16% Commercial constant currency revenue growth of 10% Adjusted gross margins of 43.5%; up 40 bps Research & development spen
Slide 11: Full Year Results
11 Full Year Results Revenue of $1.8 billion, up 2%; up 3% constant currency Medical constant currency revenue growth of 1% Aerospace constant currency revenue growth of 7% Commercial constant currency revenue growth of 16% Adjusted gross Margins of 44.4%; up 60 bps Research & development spending u
Slide 12: Fourth Quarter Segment Revenue Review
12 FOURTH QUARTER SEGMENT REVENUE REVIEW
Slide 13: Medical Q4'10 Revenue
13 Medical Critical Care Surgical Care Cardiac Care OEM 0.67 0.19 0.04 0.1 North America EMEA Asia / Latin America 0.52 0.34 0.14 Q4'10 Revenue Sales = $386.3 million, up 1% constant currency Q4'10 Constant Currency Revenue Results Critical Care: $257.7 million, up 2% Vascular access - flat Anesthes
Slide 14: Aerospace and Commercial Q4'10 Revenue
14 Non-Core Assets Cargo Systems Cargo Containers 0.72 0.28 Aerospace - Q4'10 Revenue Sales = $59.1 million, up 16% constant currency Narrow-body cargo loading system unit volume up OEM wide-body sales down Improved spare & repair sales Significant improvement in container sales due to improved end-
Slide 15: 2011 Outlook
2011 OUTLOOK Teleflex:
Slide 16: 2011 Outlook
16 2011 Outlook Revenue between $1.81 billion and $1.84 billion Adjusted cash earnings per share in the range of $4.95 to $5.15
Slide 17: Question & Answer
QUESTION & ANSWER Teleflex:
Slide 18: Appendices
APPENDICES Teleflex:
Slide 19: Appendix A - Medical Segment Review
19 Appendix A - Medical Segment Review
Slide 20: Appendix B - Aerospace Segment Review
20 Appendix B - Aerospace Segment Review
Slide 21: Appendix C - Commercial Segment Review
21 Appendix C - Commercial Segment Review
Slide 22: Appendix D - Reconciliation of Medical Operating Profit and Margins
22 Appendix D - Reconciliation of Medical Operating Profit and Margins
Slide 23: Appendix E - Reconciliation of Teleflex Gross Profit and Margins
23 Appendix E - Reconciliation of Teleflex Gross Profit and Margins
Slide 24: Appendix F - Reconciliation of Teleflex SG&A Expenses
24 Appendix F - Reconciliation of Teleflex Selling, General and Administrative Expenses
Slide 25: Appendix G - Reconciliation of Teleflex Operating Expenses
25 Appendix G - Reconciliation of Teleflex Operating Expenses
Slide 26: Appendix H - Special Charge Income Statement Classification Summary
26 Appendix H - Special Charge Income Statement Classification Summary
Slide 27: Appendix I - Quarter-to-Date Reconciliation of Cash EPS
27 Appendix I - Quarter-to-Date Reconciliation of Teleflex Cash EPS Excluding Special Charges
Slide 28: Appendix J - Year-to-Date Reconciliation of Cash EPS
28 Appendix J - Year-to-Date Reconciliation of Teleflex Cash EPS Excluding Special Charges
Slide 29: Appendix K - Reconciliation of Medical Constant Currency Revenue Growth
29 Appendix K - Quarter and Year-to-Date Reconciliation of Medical Constant Currency Revenue Growth
Slide 30: Appendix L - Reconciliation of Teleflex Constant Currency Revenue Growth
30 Appendix L - Quarter and Year-to-Date Reconciliation of Teleflex Incorporated Constant Currency Revenue Growth
Slide 31: Appendix M - Critical Care
31 Appendix M - Critical Care Vascular Access Respiratory Urology Anesthesia 0.45 0.18 0.15 0.22 North America EMEA Asia / Latin America 0.48 0.36 0.16 Q4'10 Revenue Vascular sales flat Respiratory sales flat Urology sales up 8% Anesthesia sales up 2% End Market Growth Drivers Infection prevention -
Slide 32: Appendix N - Surgical Care
32 Appendix N - Surgical Care North America EMEA Asia / Latin America 0.5 0.37 0.13 Q4'10 Revenue Increased sales of ligation and closure devices Instrument sales essentially flat versus prior year quarter Minimally invasive surgical techniques Technology / product advances Emerging markets Instrume
Slide 33: Appendix O - Cardiac Care
33 Appendix O - Cardiac Care North America EMEA Asia / Latin America 0.31 0.48 0.21 Q4'10 Revenue Voluntary recall of 5800 Series Intra-Aortic Balloon Catheters negatively impacted sales in Q4'10 Emerging markets Technology innovation Aging population Pumps Catheters 0.3 0.7 End Market Growth Driver
Slide 34: Appendix P - OEM
34 Appendix P - OEM Q4'10 Revenue Rebound in orthopedic device sales drives constant currency growth Technology innovation Speed to market Demographics Increased regulatory scrutiny on suppliers Specialty Products Orthopedic Products 0.76 0.24 North America EMEA 0.86 0.14 End Market Growth Drivers S
Slide 35: Appendix Q - Fourth Quarter Income Statement from Continuing Operations
35 Appendix Q - Fourth Quarter Income Statement from Continuing Operations Amounts in Millions, except per share
Slide 36: Appendix R - Fourth Quarter EPS Reconciliation
36 Appendix R - Fourth Quarter EPS Reconciliation from Continuing Operations
Slide 37: Appendix S - Year-to-Date Income Statement from Continuing Operations
37 Appendix S - Year-to-Date Income Statement from Continuing Operations Amounts in Millions, except per share
Slide 38: Appendix T - Year-to-Date EPS Reconciliation
38 Appendix T - Year-to-Date EPS Reconciliation from Continuing Operations
Slide 39: Appendix U - Year-to-Date Cash Flow Summary
39 Appendix U - Year-to-Date Cash Flow Summary ($ in Millions)
Slide 40: Appendix V - Reconciliation of Return on Equity
40 Appendix V - Reconciliation of Teleflex Incorporated Return on Equity
Slide 41: Appendix W - Reconciliation of 2011 Outlook EPS Guidance
41 Appendix W - Reconciliation of 2011 Outlook Earnings per Share Guidance